BioSpace News Archive

3M has paid dividends to its shareholders without interruption for more than 100 years.

Net revenue increased 6.3% to $7.1 million from $6.7 million during the three months ended March 31, 2017

CEVEC Pharmaceuticals GmbH announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP(R)Go technology.

Dolomite Bio announced a collaboration to combine Partek’s single cell data analysis capabilities with Dolomite Bio’s microfluidic droplet-based single cell technology.

Debiopharm International SA announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Debio 1347, an FGFR 1-3 Inhibitor, for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today the formation of an independent Steering Committee to guide the Phase 3 global clinical development program for PTI-428.

-- Triple stack innovation demonstrates value across multiple growing conditions, enhancing crop productivity, climate stability and stewardship --

EarlySign’s Predictive Models to Help Kaiser Manage Patient Intervention Efficiently for Best Health Outcomes

Webcast Available Through Gilead Corporate Website

--Patient enrollment into the study expected to begin by the end of June 2018--